Institute of Cellular and Intracellular Symbiosis, Ural Branch of the Russian Academy of Sciences, Orenburg, Russia.
Probiotics Antimicrob Proteins. 2023 Jun;15(3):588-600. doi: 10.1007/s12602-021-09876-3. Epub 2021 Nov 22.
The purpose of this study was to evaluate the probiotic characteristics and safety and to study the antifungal activity of C. amycolatum ICIS 9 and C. amycolatum ICIS 53 against Candida spp. The probiotic potential and safety properties were assessed by standard parameters. Both strains showed good survival at pH 3 for 3 h and high tolerance to 0.3% bile salts after 4 h of incubation. The indicators of hydrophobicity, autoaggregation, and surface tension for ICIS 9 were 89.43% (n-hexane) and 73.96% (xylene) and ranged from 13.13 to 39.86% and 34.27 mN/m, respectively. For ICIS 53, they were 59.95% (n-hexane) and 45.68% (xylene), from 35.58 to 51.53% and 32.40 mN/m, respectively. The strains ICIS 9 and ICIS 53 exhibited varying levels of coaggregation with all eight examined bacterial pathogens. The ICIS 9 strain was resistant to amikacin, amoxicillin, clarithromycin, chloramphenicol, ciprofloxacin, and gentamycin. ICIS 53 was resistant only to ciprofloxacin. The cell-free supernatant of strains ICIS 9 and ICIS 53 showed good antimicrobial and antibiofilm activity against 10 pathogenic vaginal and intestinal isolates of Candida spp. The CFS of ICIS 9 was more active against intestinal isolates, and the CFS of ICIS 53 showed good antimicrobial activity against vaginal isolates while inhibiting the growth of 2 out of 5 Candida spp. isolated from the intestine. Both of the strains were capable of reducing the biofilm formation of Candida fungi. In the case of the vaginal isolates of C. krusei V1, the results showed that the inhibition levels of ICIS 9 and ICIS 53 were 36.75 and 11.4%, respectively. In the case of C. albicans (V2, V3, V7, and V8), the inhibition of biofilm formation was no more than 7.07%. ICIS 9 and ICIS 53 also significantly inhibited biofilm formation of C. krusei 2613 intestinal isolates by 42.75 and 41.87%, respectively, with ICIS 9 inhibiting biofilm formation of C. albicans (2607, 2311, 2615, and 2615) from 3.38 to 15.69% and ICIS 53 from 5.95 to 23.48%. None of the strains showed DNase, haemolytic, or gelatinase activities. The results obtained revealed that ICIS 9 and ICIS 53 have safe properties and have the potential to be developed as probiotics.
本研究旨在评估解淀粉芽胞杆菌 ICIS9 和 ICIS53 的益生菌特性和安全性，并研究其对念珠菌属真菌的抗真菌活性。通过标准参数评估益生菌潜力和安全性特性。两种菌株在 pH3 下 3 小时和 0.3%胆汁盐孵育 4 小时后均具有良好的耐受性。ICIS9 的疏水性、自动聚集和表面张力指标分别为 89.43%（正己烷）和 73.96%（二甲苯），范围为 13.13%至 39.86%和 34.27 mN/m。对于 ICIS53，它们分别为 59.95%（正己烷）和 45.68%（二甲苯），范围为 35.58%至 51.53%和 32.40 mN/m。菌株 ICIS9 和 ICIS53 与所有 8 种检测到的细菌病原体均表现出不同程度的共聚。ICIS9 株对阿米卡星、阿莫西林、克拉霉素、氯霉素、环丙沙星和庆大霉素具有抗性。ICIS53 仅对环丙沙星有抗性。菌株 ICIS9 和 ICIS53 的无细胞上清液对 10 种致病性阴道和肠道念珠菌属分离株表现出良好的抗菌和抗生物膜活性。ICIS9 的 CFS 对肠道分离株更有效，而 ICIS53 的 CFS 对阴道分离株表现出良好的抗菌活性，同时抑制了 5 种从肠道分离的念珠菌属中的 2 种的生长。两种菌株均能减少念珠菌属真菌的生物膜形成。对于阴道分离株 C. krusei V1，结果表明 ICIS9 和 ICIS53 的抑制水平分别为 36.75%和 11.4%。对于 C. albicans（V2、V3、V7 和 V8），生物膜形成的抑制不超过 7.07%。ICIS9 和 ICIS53 还分别显著抑制了肠道分离株 C. krusei 2613 的生物膜形成，抑制率分别为 42.75%和 41.87%，ICIS9 抑制了 C. albicans（2607、2311、2615 和 2615）的生物膜形成，抑制率为 3.38%至 15.69%，而 ICIS 53 的抑制率为 5.95%至 23.48%。两种菌株均无 DNase、溶血或明胶酶活性。研究结果表明，ICIS9 和 ICIS53 具有安全特性，具有作为益生菌开发的潜力。
